The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
|Videos|October 6, 2017
Dr. Wagstaff on the Survival Benefit of Immunotherapy in Bladder Cancer
Author(s)John Wagstaff, MD
John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Advertisement
John Wagstaff, MD, professor at Swansea University Medical School, discusses the survival benefit of immunotherapy for patients with bladder cancer.
Most of the trials have been conducted with single-agent checkpoint inhibitors, explains Wagstaff. These trials showed response rates in the second-line setting of 15% to 25%.
Patients with melanoma who respond to immunotherapy see years of survival benefit; however, longer follow-up is needed to determine if this is the case in bladder cancer, states Wagstaff.
Advertisement
Related to this article
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
The FDA approved lirafugratinib in FGFR2+ cholangiocarcinoma and belzutifan plus lenvatinib in advanced ccRCC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
The FDA has approved belzutifan (Welireg) plus lenvatinib (Lenvima) for use in patients with advanced renal cell carcinoma with a clear cell component after PD-1 or PD-L1 inhibition.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
Advertisement
Advertisement
Trending on OncLive
1
Savolitinib Plus Osimertinib NDA Submitted to FDA for MET-Driven, EGFR-Mutated NSCLC After EGFR TKI
2
FDA Grants Priority Review to Elinzanetant for Endocrine Therapy–Associated Vasomotor Symptoms in HR+ Breast Cancer
3
Calculating the Real Cost of False Positive Findings in Cancer Screening
4
Cilta-Cel Shows Long-Term Treatment-Free Remissions in Lenalidomide-Refractory Myeloma
5